Get the Stockscreener App
2.31
1.70%
-0.04
After Hours:
2.30
-0.01
-0.43%
Veru Inc stock is traded at $2.31, with a volume of 97,493.
It is down -1.70% in the last 24 hours and down -0.43% over the past month.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
See More
Previous Close:
$2.35
Open:
$2.38
24h Volume:
97,493
Relative Volume:
1.75
Market Cap:
$37.08M
Revenue:
$3.86M
Net Income/Loss:
$-19.20M
P/E Ratio:
-3.1739
EPS:
-0.7278
Net Cash Flow:
$-24.88M
1W Performance:
+9.48%
1M Performance:
-0.43%
6M Performance:
-5.33%
1Y Performance:
-53.66%
1-Day Range:
$2.23
$2.40
1-Week Range:
$2.1009
$2.40
52-Week Range:
$2.05
$7.40
Veru Inc Stock (VERU) Company Profile
Name
Veru Inc
Sector
Industry
Phone
(312) 595-9123
Address
2916 N. MIAMI AVENUE, MIAMI, FL
Compare VERU vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VERU
Veru Inc
|
2.31 | 37.72M | 3.86M | -19.20M | -24.88M | -0.7278 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Veru Inc Stock (VERU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Initiated | Canaccord Genuity | Buy |
| May-14-24 | Initiated | B. Riley Securities | Buy |
| Mar-28-24 | Initiated | Raymond James | Outperform |
| Jun-07-23 | Upgrade | Jefferies | Underperform → Hold |
| Apr-13-21 | Initiated | Jefferies | Buy |
| Feb-09-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-21-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-20-19 | Initiated | Oppenheimer | Outperform |
| Jul-03-18 | Initiated | Maxim Group | Buy |
View All
Veru Inc Stock (VERU) Latest News
Veru 2Q Loss $2.74M >VERU - Moomoo
Nvidia (NVDA) CEO Discusses Arrival of Veru CPUs in AI Labs - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
VERU Maintained by Oppenheimer -- Price Target Lowered to $24 - GuruFocus
Oppenheimer Adjusts Price Target on Veru to $24 From $25, Maintains Outperform Rating - marketscreener.com
Veru Inc. Earnings Call Highlights Clinical Momentum - The Globe and Mail
Veru 2Q Loss/Shr 12c >VERU - Moomoo
Veru Inc. (NASDAQ:VERU) Q2 2026 Earnings Call Transcript - Insider Monkey
Veru outlines Q1 2027 interim readout for 36-week enobosarm plateau analysis - MSN
Veru SEC Filings - Stock Titan
Veru Inc (VERU) Q2 2026 Earnings Call Highlights: Promising Clin - GuruFocus
Veru Q2 2026: -$0.12 EPS Tops Estimates — Deep Dive - AlphaStreet
Q2 2026 Veru Inc Earnings Call Transcript - GuruFocus
Veru Inc. (VERU) Reports Positive Phase IIb Trial Results and On - GuruFocus
Veru (VERU) Q2 2026 Earnings Transcript - AOL.com
Veru Posts Narrower Q2 2026 Loss of -$0.12, 57.1% Better Than Forecast - AlphaStreet
Veru Q2 2026 earnings preview - MSN
Veru Releases Q2 2026 Financial Results - AlphaStreet
Veru Inc. 2026 Q2 Financial Report: Key Risks, Results, and Clinical Trial Updates - Minichart
Veru Reports Q2 2026 Results and Progress on Phase 2b PLATEAU Trial for Enobosarm Plus Semaglutide in Obesity Treatment - Minichart
Veru reports Q2 fiscal 2026 results, obesity trial enrolling By Investing.com - Investing.com India
Veru Inc. (VERU) Reports Q2 Earnings, EPS Exceeds Expectations - GuruFocus
Veru Inc (VERU.US) is scheduled to release its earnings report on May 13. - 富途牛牛
VERU: Phase II-B data show enobosarm preserves muscle and function, with improved financials and strong cash - TradingView
VERU Reports Financial Growth and Clinical Trial Progress - GuruFocus
Veru Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: Veru Inc Q2 2026 shows improved financials - Investing.com
VERU: Enobosarm preserves muscle and function in older obese patients; losses narrowed, cash improved - TradingView
Earnings call transcript: Veru Inc Q2 2026 shows improved financials By Investing.com - Investing.com Nigeria
VERU INC. 3Q 2026: Revenue $0 Net loss $2.74M, EPS $(0.12) — 10-Q Summary - TradingView
Veru (NASDAQ: VERU) narrows loss but warns on going concern and funding needs - Stock Titan
Transcript: Veru Q2 2026 Earnings Conference Call - Yahoo Finance
Veru reports Q2 fiscal 2026 results, obesity trial enrolling - Investing.com UK
Veru reports Q2 fiscal 2026: Net loss narrows to $2.7M, cash $27.6M - TradingView
Veru (VERU) trims losses and advances PLATEAU Phase 2b obesity trial - Stock Titan
Veru Inc. Announces Active Enrollment in Phase 2b PLATEAU Study of Enobosarm and Semaglutide with Interim Analysis Expected in 2027 - Quiver Quantitative
Veru obesity trial tests add-on to semaglutide to break weight-loss plateau - Stock Titan
Press Release: Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress - Moomoo
TradingKey - TradingKey
Veru Inc expected to post a loss of 28 cents a shareEarnings Preview - TradingView
Veru Inc Stock (VERU) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):